Erasca

(NASDAQ) ERAS

Current Price$12.48

Market Cap$3.58B

Since IPO (2021)-34%

5 YearN/A

1 Year+843%

1 Month-46%

Erasca Financials at a Glance

Market Cap

$3.58B

Revenue (TTM)

$0.00

Net Income (TTM)

-$277.02M

EPS (TTM)

-$0.93

P/E Ratio

-12.33

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$12.48

Volume

6,378,820.389

Open

$11.59

Price

$12.48

Volume

6,378,820.389

Open

$11.59

Previous Close

$12.47

Daily Range

$11.59 - $12.87

52-Week Range

$1.07 - $24.28

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$12.48

Volume

6,378,820.389

Open

$11.59

Previous Close

$12.47

Daily Range

$11.59 - $12.87

52-Week Range

$1.07 - $24.28

ERAS News

Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally

Sara AppinoMay 18, 2026

Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More

Jonathan PoncianoMay 17, 2026

Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy

Cory RenauerMay 16, 2026

Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700%

Jonathan PoncianoMay 14, 2026

Stock Market Today, April 28: Erasca Plunges After Patient Death in Early Cancer Drug Trial

Josh Kohn-LindquistApr 28, 2026

Page 1

ERAS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Erasca

Industry

Biotechnology

Sector

Health Care

Employees

103

CEO

Jonathan E. Lim, MD

Website

www.erasca.com

Headquarters

San Diego, CA 92121, US

ERAS Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-70%

Return on Capital

-33%

Return on Assets

-60%

Earnings Yield

-8.11%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.58B

Shares Outstanding

310.99M

Volume

6.38M

Avg. Volume

6.77M

Financials (TTM)

Gross Profit

-$3.11M

Operating Income

-$131.41M

EBITDA

-$128.30M

Operating Cash Flow

-$95.46M

Capital Expenditure

-$128.00K

Free Cash Flow

-$95.58M

Cash & ST Invst.

$276.08M

Total Debt

$47.14M

Erasca Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$723.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$3.58B

N/A

Market Cap/Employee

$34.72M

N/A

Employees

103

N/A

Net Income

-$183.44M

-492.4%

EBITDA

-$37.19M

-6.8%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$197.84M

-22.0%

Accounts Receivable

$3.30M

+32.0%

Inventory

$0.00

N/A

Long Term Debt

$40.70M

-11.6%

Short Term Debt

$5.25M

+9.6%

Return on Assets

-60.06%

N/A

Return on Invested Capital

-32.95%

N/A

Free Cash Flow

-$27.42M

+13.3%

Operating Cash Flow

-$27.38M

+13.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

IOVAIovance Biotherapeutics, Inc.

IOVAIovance Biotherapeutics, Inc.$4.37+6.59%

MLTXMoonLake Immunotherapeutics

MLTXMoonLake Immunotherapeutics$18.41+0.99%

AVBPArriVent BioPharma, Inc. Common Stock

AVBPArriVent BioPharma, Inc. Common Stock$27.47-1.68%

CRVSCorvus Pharmaceuticals, Inc.

CRVSCorvus Pharmaceuticals, Inc.$12.93+0.78%

MBXMBX Biosciences, Inc. Common Stock

MBXMBX Biosciences, Inc. Common Stock$31.88+0.41%

MGTXMeiraGTx Holdings plc

MGTXMeiraGTx Holdings plc$9.89+3.02%

CTMXCytomX Therapeutics, Inc.

CTMXCytomX Therapeutics, Inc.$3.81+3.25%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

ASTCAstrotech

ASTCAstrotech$13.81+4.59%

NOKNokia

NOKNokia$15.68-0.05%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.92+0.01%

FFord Motor Company

FFord Motor Company$15.88+0.04%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$81.67-0.00%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$39.44+0.00%

SIDUSidus Space

SIDUSidus Space$6.09-0.02%

Questions About ERAS

What is the current price of Erasca?

Erasca is trading at $12.47 per share.

What is the 52-week range for Erasca?

Over the past 52 weeks, Erasca has traded between $1.07 and $24.28.

How much debt does Erasca have?

As of the most recent reporting period, Erasca reported total debt of $45.95M.

How much cash does Erasca have on hand?

Erasca reported $47.26M in cash and cash equivalents in its most recent financial results.

What is Erasca’s dividend yield?

Erasca does not currently have a dividend yield.

Erasca

Erasca Financials at a Glance

ERAS News

Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally

Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More

Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy

Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700%

Stock Market Today, April 28: Erasca Plunges After Patient Death in Early Cancer Drug Trial

Erasca CMO's Direct Stake Hit Zero. Her Options Position Didn't

Erasca Insider Sells $671K as Stock Jumps 189% This Past Year

Erasca Narrows Loss 46% in Fiscal Q2

ERAS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Erasca

ERAS Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Erasca Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ERAS

What is the current price of Erasca?

What is the 52-week range for Erasca?

How much debt does Erasca have?

How much cash does Erasca have on hand?

What is Erasca’s dividend yield?

Premium Investing Services